Compare VSTS & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VSTS | KROS |
|---|---|---|
| Founded | 1936 | 2015 |
| Country | United States | United States |
| Employees | 18150 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 996.9M | 565.0M |
| IPO Year | N/A | 2020 |
| Metric | VSTS | KROS |
|---|---|---|
| Price | $6.87 | $21.50 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 4 | 15 |
| Target Price | $5.95 | ★ $22.20 |
| AVG Volume (30 Days) | ★ 3.2M | 1.1M |
| Earning Date | 01-30-2026 | 11-05-2025 |
| Dividend Yield | ★ 0.46% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.57 |
| Revenue | ★ $2,734,839,000.00 | $246,718,000.00 |
| Revenue This Year | $1.47 | $6,876.34 |
| Revenue Next Year | $3.06 | N/A |
| P/E Ratio | ★ N/A | $13.66 |
| Revenue Growth | N/A | ★ 37798.31 |
| 52 Week Low | $3.98 | $9.12 |
| 52 Week High | $16.68 | $22.55 |
| Indicator | VSTS | KROS |
|---|---|---|
| Relative Strength Index (RSI) | 59.60 | 72.63 |
| Support Level | $7.10 | $20.73 |
| Resistance Level | $7.70 | $22.20 |
| Average True Range (ATR) | 0.46 | 0.96 |
| MACD | 0.03 | 0.20 |
| Stochastic Oscillator | 69.09 | 83.45 |
Vestis Corp is a provider of uniform rentals and workplace supplies across the United States and Canada. It provides uniforms, mats, towels, linens, restroom supplies, first-aid supplies, safety products, and other workplace supplies. The Company serves customers ranging from small, family-owned operations with a single location to large corporations and national franchises with multiple locations. The company operates in the United States and Canada as reportable segments. The company earns the majority of its revenue from the United States.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.